Clinical Trial Update: Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial comparing denintuzumab mafodotin plus RICE versus RICE alone in diffuse large B-cell lymphoma; the study is terminated with results posted in 2019…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma Grade 3b
• Lymphoma B-cell
• Lymphoma Follicular Grade 3b

Drugs mentioned

• RICE (R-CHOP-like regimen? (RICE))
• denintuzumab mafodotin (denintuzumab mafodotin)

Snippet

Sponsor: Seagen Inc. | Conditions: Lymphoma, B-cell, Lymphoma, Large B-Cell, Diffuse | Phase 2 | Status: TERMINATED | Results posted: 2019-05-17